Pages that link to "Q39735076"
Jump to navigation
Jump to search
The following pages link to The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy (Q39735076):
Displaying 50 items.
- Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma (Q26824310) (← links)
- Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application (Q26858779) (← links)
- The future of immune checkpoint therapy (Q28259862) (← links)
- Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity (Q28486600) (← links)
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial (Q30407940) (← links)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (Q33689478) (← links)
- Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells (Q33910157) (← links)
- Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. (Q34083483) (← links)
- Therapy for metastatic melanoma: the past, present, and future. (Q34183225) (← links)
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. (Q34403480) (← links)
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer (Q34414152) (← links)
- Phosphatidylinositol 3-kinase-independent signaling pathways contribute to ICOS-mediated T cell costimulation in acute graft-versus-host disease in mice (Q35053704) (← links)
- An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer (Q36069642) (← links)
- Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. (Q36103115) (← links)
- Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy? (Q36449290) (← links)
- Biomarkers on melanoma patient T cells associated with ipilimumab treatment (Q36480617) (← links)
- The role of B7 family molecules in hematologic malignancy (Q36584814) (← links)
- Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study (Q36711007) (← links)
- MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints (Q36785139) (← links)
- Identification of potential biomarkers from microarray experiments using multiple criteria optimization (Q36804902) (← links)
- Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells (Q36823732) (← links)
- ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells (Q36866139) (← links)
- Emerging options for the treatment of melanoma - focus on ipilimumab (Q37031656) (← links)
- Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis (Q37601946) (← links)
- Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity (Q37651860) (← links)
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy (Q37689378) (← links)
- CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy (Q37732951) (← links)
- Targeting costimulatory molecules to improve antitumor immunity. (Q38002404) (← links)
- Advances in the management of melanoma: targeted therapy, immunotherapy and future directions (Q38068205) (← links)
- B7 family checkpoint regulators in immune regulation and disease (Q38129635) (← links)
- Immune modulation in cancer with antibodies (Q38159801) (← links)
- Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma (Q38160837) (← links)
- The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy (Q38304438) (← links)
- Immune checkpoint combinations from mouse to man. (Q38306150) (← links)
- Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some (Q38413904) (← links)
- Prognostic and predictive biomarkers in melanoma: an update (Q38653619) (← links)
- Immunotherapy for advanced melanoma: future directions. (Q38711163) (← links)
- PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques. (Q38728448) (← links)
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy (Q38743794) (← links)
- Biomarkers associated with checkpoint inhibitors (Q38819537) (← links)
- What does the future hold for immunotherapy in cancer? (Q38856436) (← links)
- Immunoregulatory functions of VISTA. (Q38930123) (← links)
- Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity (Q39143599) (← links)
- ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. (Q39873712) (← links)
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (Q40262479) (← links)
- The inducible costimulator augments Tc17 cell responses to self and tumor tissue. (Q41551980) (← links)
- Tumor immunology: multidisciplinary science driving basic and clinical advances (Q41853258) (← links)
- Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy (Q42085981) (← links)
- A systems biology approach to personalizing therapeutic combinations (Q42791397) (← links)
- Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. (Q42968783) (← links)